U.S. Sen. Joe Manchin, D-W.Va., applauded the Food and Drug Administration’s (FDA) decision to strengthen training and prescribing practices for immediate release opioids by adding them to the FDA’s Risk Evaluation and Mitigation Strategy (REMS).
U.S. Sen. Joe Manchin, D-W.Va., applauded the Food and Drug Administration’s (FDA) decision to strengthen training and prescribing practices for immediate release opioids by adding them to the FDA’s Risk Evaluation and Mitigation Strategy (REMS).